MedTrace Logo

Safety, Efficacy and Pharmacokinetics of ALD403

NCT01772524 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2016-01-08

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.

Conditions

Interventions

BIOLOGICAL

ALD403

DRUG

Placebo

Sponsors & Collaborators

  • Alder Biopharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeff Smith, MD · Alder Biopharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-12-31
Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01772524 on ClinicalTrials.gov